Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 17/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24986399 | 0.85 | AR (0.47) | ARLRRK2 | |
| SCHEMBL12724980 | 0.83 | AR (0.39) | ARSLC22A12 | |
| SCHEMBL19734892 | 0.80 | AR (0.44) | ARSLC22A12 | |
| SCHEMBL311743 | 0.78 | AR (0.44) | AR | |
| SCHEMBL22917962 | 0.78 | AR (0.47) | ARLRRK2 | |
| SCHEMBL8915338 | 0.78 | RAPGEF4 (0.41) | — | |
| SCHEMBL18179223 | 0.78 | TRPV4 (0.45) | ARSLC22A12 | |
| SCHEMBL30855350 | 0.78 | RAPGEF4 (0.41) | — | |
| SCHEMBL28391831 | 0.76 | AR (0.51) | AR | |
| SCHEMBL12812120 | 0.76 | AR (0.53) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2016174551-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | ESR1, ESRRA, ESR2 | AR 44/4885LRRK2 2542/4885SLC22A12 2546/4885 |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | ESR1, ESRRA, ESR2 | AR 44/4885LRRK2 2542/4885SLC22A12 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.